AstraZeneca has made a new drug with a combination of saxagliptin and dapagliflorzin to combat diabetes, and have spent quite a lot of money and time developing this drug.
The drug was awaiting USFDA clearance to hit markets. However, the regulatory body is still not conviced about this drug’s efficacy and safety.
For this reason, the company has been ordered to conduct more clinical trials before they re-examine AstraZeneca’s application again.
